Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7176156 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SRD5A2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL68390 | 0.80 | SRD5A2 (0.69) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL7366568 | 0.80 | PLA2G10 (0.59) | ALDH1A1TSHRKMT2ACA1CA2 | |
| SCHEMBL211305 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL4141280 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL11139354 | 0.80 | CYP3A4 (0.42) | ALDH1A1TSHRTP53KMT2ASMN1; SMN2 | |
| SCHEMBL4968695 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| SCHEMBL2225820 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| Hydrochloric Acid SCHEMBL25188150 | 0.78 | SRD5A2 (0.67) | ALDH1A1TSHRTP53SRD5A2KMT2A | |
| Hydrochloric Acid SCHEMBL7133360 | 0.78 | SRD5A2 (0.67) | ALDH1A1TSHRTP53SRD5A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| US-4992544-A | Intermediates for b-lactam antibiotics and b-lactamase inhibitor | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0244195-A1 | 2-Vinylpenams and process | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 1987-11-04 | — | — | EP | disclosed |
| US-4604386-A | CONTROL OF GRAMPOSITIVE BACTERIA | ELI LILLY AND COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0168222-A2 | 3-(Alkynylalkyloxy) Cephalosporins | ELI LILLY AND COMPANY (US) | 1986-01-15 | — | — | EP | disclosed |
| US-4560749-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| US-4521598-A | 3-Azidocephalosporins | ELI LILLY AND COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0136177-A2 | 3-Azidocephalosporins as intermediates and novel antibacterial agents | ELI LILLY AND COMPANY (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4060688-A | Cephalosporin intermediates | ELI LILLY AND COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ALDH1A1 578/4885TSHR 689/4885TP53 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.